MetaCap

Allarity Therapeutics (ALLR) vs Seres Therapeutics (MCRB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Seres Therapeutics is the larger company by market cap ($12.6 million vs $12.6 million), about 1.0 times the size. Seres Therapeutics converts more of its revenue into profit, with a net margin of 721.9% versus -3509.7%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALLR-20.22%MCRB-54.41%
+18%-20%-58%
Oct 7, 20261 yearNov 20, 2026
ALLR-20.71%MCRB-54.24%
+3%-27%-57%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALLR versus MCRB key metrics
MetricALLRMCRB
Share price$0.785$1.24
Market cap$12.56M$12.64M
1-day change-9.25%-6.77%
YTD return-27.31%—
1-year return-25.94%—
EPS (TTM)$-0.79$-5.01
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$320.00K$789.00K
Net income (latest FY)$-11.23M$5.70M
Operating margin-3939.06%-11910.14%
Net margin-3509.69%721.93%
52-week high$1.84$18.86
52-week low$0.769$1.20
Distance from 52-week high-57.34%-93.43%
Analyst consensusnonenone
Avg. price target upside+1301.27%+1270.97%
Average volume131.74K74.83K
Shares outstanding16.00M10.20M
Employees766
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Seres Therapeutics is more profitable, keeping 721.9 cents of every revenue dollar as net income versus -3509.7 cents for Allarity Therapeutics.

About Allarity Therapeutics

ALLR stock →

Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

About Seres Therapeutics

MCRB stock →

Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation.

Health Care · Biotechnology: Pharmaceutical Preparations · 66 employees

ALLR vs MCRB FAQ

Which is bigger, Allarity Therapeutics or Seres Therapeutics?

Seres Therapeutics (MCRB) is larger, with a market capitalization of $12.64M compared with $12.56M for Allarity Therapeutics (ALLR).

Are Allarity Therapeutics and Seres Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons